{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:19:26Z","timestamp":1780478366079,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.urolonc.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:32:40Z","timestamp":1739795560000},"page":"398.e1-398.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Functional, oncological, regret and complications following partial gland cryo-ablation for low-risk prostate cancer associated with MPMRI targets"],"prefix":"10.1016","volume":"43","author":[{"given":"Herbert","family":"Lepor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majlinda","family":"Tafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wysock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.02.001_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.001_bib0002","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.urolonc.2025.02.001_bib0003","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active Surveillance for the management of localized prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.001_bib0004","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.urology.2009.12.075","article-title":"Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy","volume":"76","author":"Mufarrij","year":"2010","journal-title":"Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.001_bib0005","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.001_bib0006","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"Decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.001_bib0007","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.juro.2016.02.2963","article-title":"How active is active surveillance? Intensity of follow-up during active surveillance for prostate cancer in the United States","volume":"196","author":"Loeb","year":"2016","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.02.001_bib0008","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00345-016-1782-x","article-title":"Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project","volume":"34","author":"Postema","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.001_bib0009","article-title":"The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement","author":"Javier-DesLoges","year":"2023","journal-title":"Prostat Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.001_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","article-title":"New and established technology in focal ablation of the prostate: a systematic review","volume":"71","author":"Valerio","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.02.001_bib0011","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2018.05.121","article-title":"Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended follow-up and analyses of effectiveness","volume":"200","author":"Gill","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.001_bib0012","doi-asserted-by":"crossref","unstructured":"Wysock J.S., Becher E., Gogaj R., Velazquez N., Lepor H. et al. Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate cancer prostatic dis. 2021;24(1):114-119. doi: 10.1038\/s41391-020-0244-0.","DOI":"10.1038\/s41391-020-0244-0"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.001_bib0013","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JU.0000000000003569","article-title":"Biopsy assessment of oncologic control 3 years following primary partial gland cryoablation: a prospective cohort study of men with intermediate-risk prostate cancer","volume":"210","author":"Wysock","year":"2023","journal-title":"Urol"},{"key":"10.1016\/j.urolonc.2025.02.001_bib0014","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association Symptom Index for Benign Prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.001_bib0015","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0149-2918(01)80138-7","article-title":"Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men","volume":"23","author":"Cappelleri","year":"2001","journal-title":"Clin. Ther"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.001_bib0016","doi-asserted-by":"crossref","first-page":"20.e1","DOI":"10.1016\/j.urolonc.2023.10.003","article-title":"Patient-reported prostate cancer treatment regret following primary partial gland cryoablation","volume":"42","author":"Lepor","year":"2024","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.02.001_bib0017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00005650-200308000-00006","article-title":"Measuring patients' perceptions of the outcomes of treatment for early prostate cancer","volume":"41","author":"Clark","year":"2003","journal-title":"Med Care"},{"issue":"27","key":"10.1016\/j.urolonc.2025.02.001_bib0018","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.02.001_bib0019","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"An J Surg Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.001_bib0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2013.03.054","article-title":"Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy","volume":"82","author":"Donin","year":"2013","journal-title":"Urology"},{"issue":"24","key":"10.1016\/j.urolonc.2025.02.001_bib0021","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1001\/jama.2024.6695","article-title":"Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer","volume":"331","author":"Newcomb","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.urolonc.2025.02.001_bib0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.001_bib0023","first-page":"11128","article-title":"Early functional outcomes following partial gland cryo-ablation","volume":"29","author":"Thakker","year":"2022","journal-title":"Can J Urol"},{"key":"10.1016\/j.urolonc.2025.02.001_bib0024","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.urology.2022.10.003","article-title":"Two-year functional outcomes stratified according to baseline erectile function following partial gland cryo-ablation","volume":"171","author":"Wysock","year":"2023","journal-title":"Urology"},{"issue":"10071","key":"10.1016\/j.urolonc.2025.02.001_bib0025","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.001_bib0026","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.juro.2015.02.080","article-title":"Image guided focal therapy for Magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on Magnetic resonance imaging histology Co-registration analysis","volume":"194","author":"Le Nobin","year":"2015","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.001_bib0027","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0022-5347(05)67028-0","article-title":"Filling and voiding symptoms in the American Urological Association symptom index: the value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia","volume":"164","author":"Barry","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.001_bib0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euo.2018.12.004","article-title":"Patient-reported outcomes following treatment of localised prostate cancer and their association with regret about treatment choices","volume":"3","author":"van Stam","year":"2020","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:10:03Z","timestamp":1747325403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1078143925000274"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional, oncological, regret and complications following partial gland cryo-ablation for low-risk prostate cancer associated with MPMRI targets","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}